Author: Contributing Writer

MedicalResearch.com Interview with: [caption id="attachment_60185" align="alignleft" width="161"]Aristotelis Tsirigos, Ph.D.Professor of Medicine and Pathology Co-director, Precision Medicine Director, Applied Bioinformatics Laboratories New York University School of Medicine Dr. Tsirigos[/caption] Aristotelis Tsirigos, Ph.D. Professor of Medicine and Pathology Co-director, Precision Medicine Director, Applied Bioinformatics LaboratoriesNew York University School of Medicine MedicalResearch.com: What is the background for this study? Response: Pancreatic cancer is one of the most lethal types of cancer with only 12% of patients surviving more than 5 years after diagnosis. One of the main reasons behind the dismal prognosis is the complexity of the tumor. Pancreatic cancer cells are very heterogenous and interact with different types of non-malignant cells in what is known as the tumor microenvironment.

The FDA has the final say on the standards and requirements for medical device manufacturing. Its risk-based classification system is an important part of protecting the industry. Although there are several regulations to follow, compliance is not a problem for the many medical devices worldwide. The Demand Contract manufacturing for medical devices...

MedicalResearch.com Interview with: [caption id="attachment_60166" align="alignleft" width="133"]Norman Kleiman, PhD, MSDepartment of Environmental Health Sciences
Mailman School of Public Health
Columbia University, New York, NY Dr. Kleiman[/caption] Norman Kleiman, PhD, MS Department of Environmental Health Sciences Mailman School of Public Health Columbia University, New York, NY MedicalResearch.com: What is the background for this study? Response: The 1986 Chornobyl nuclear disaster caused the evacuation of 300,000 persons from the cities and villages surrounding the nuclear power plant complex. Pets and belongings were left behind, and the Soviet authorities ordered all animals within the Chornobyl Exclusion Zone killed. Some dogs evaded destruction, and some 300+ descendants of these animals live primarily at two locations today, immediately surrounding the Nuclear Power Plant (NPP) complex and about 10 km away in Chornobyl city. What is relatively unknown to the general public is that Chornobyl is not a desolate, abandoned wasteland. Some thousands of individuals work there every day in continuing cleanup activities and at two new fuel reprocessing facilities built near the damaged reactor. These areas have been substantially remediated, and the average radiation levels are relatively modest. The dogs, which, while feral, are accustomed to human interaction, live near the workers and are not currently exposed to high radiation levels. In contrast to lower radiation levels, there is a toxic mixture of heavy metals, organics, pesticides, and unknown chemicals left over from years’ long cleanup efforts and the decay of a large former military-industrial complex at the NPP. Since 2016, the NPP authorities have brought in teams of veterinarians and volunteers to spay, neuter, and vaccinate the dogs to protect the workers and deal with a growing population. At the same time, some scientists joined the teams to obtain various kinds of biospecimens (hair, urine, feces, blood, saliva, parasites) to examine the animals’ health and learn how this toxic environment may have affected them or their offspring. Since dogs are human companion animals and live closely with us, any information we learn about health risks to the dogs may be relevant to protecting human workers and inform us about the kinds of health risks posed by ecological and environmental disasters in the future.

MedicalResearch.com Interview with: [caption id="attachment_60160" align="alignleft" width="150"]Veronica Hulstrøm MD, PhDSenior Director Clinical Project Lead for RSV Older Adults GSK Dr. Hulstrøm[/caption] Veronica Hulstrøm MD, PhD Senior Director Clinical Project Lead for RSV Older Adults GSK     MedicalResearch.com: What is the background for this study? Response: The AReSVi-006 phase III trial is designed to investigate the efficacy and safety of GSK’s respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above. The phase III trial is a randomized, placebo-controlled, double-blind, international trial with 24,966 participants who received either the investigational vaccine or placebo.

MedicalResearch.com Interview with:
Hyuna Sung, PHDHyuna Sung, PHD Senior Principal Scientist, Cancer Surveillance Research American Cancer Society Kennesaw, GA 30144
  MedicalResearch.com: What is the background for this study? Response: Triple-negative breast cancer (TNBC) accounts for 10% to 20% of all breast cancer diagnoses in the US. This subtype of breast cancer tends to spread faster and has fewer treatment options. In the US, Black women are about two-fold more likely than White women to develop TNBC.

MedicalResearch.com Interview with: [caption id="attachment_60156" align="alignleft" width="150"]Nicholas Gulati, MD, PhDDirector, Early Detection of Skin Cancer and Oncodermatology Clinic
The Kimberly and Eric J. Waldman
Department of Dermatology
Mount Sinai Health System
New York, New York Dr. Gulati[/caption] Nicholas Gulati, MD, PhD Director, Early Detection of Skin Cancer and Oncodermatology Clinic The Kimberly and Eric J. Waldman Department of Dermatology Mount Sinai Health System New York, New York MedicalResearch.com: What is the background for this study? What is dupilumab primarily used for? Response: Dupilumab is a monoclonal antibody that inhibits a specific part of the immune system known as Th2 cells, which are important in the development of various diseases including atopic dermatitis (eczema) and asthma. Therefore, dupilumab has become one of the major treatments for these conditions. Given the increasing use of this drug, it is important to understand the safety of it in terms of cancer development, as that is currently largely unknown.

[caption id="attachment_60153" align="alignleft" width="150"]Myeong-Ki Hong, MD PhDProfessor of Cardiology
Yonsei University College of Medicine
Severance Cardiovascular Hospital
Seoul, Korea Prof. Myeong-Ki Hong[/caption] MedicalResearch.com Interview with: Myeong-Ki Hong, MD PhD Professor of Cardiology Yonsei University College of Medicine Severance Cardiovascular Hospital Seoul, Korea MedicalResearch.com: What is the background for this study? Response: The background of this study was to compare the long-term clinical outcomes between the two distinct strategies regarding statin intensity in patients with coronary artery disease (CAD). One is to titrate statin intensity to meet a target low-density lipoprotein cholesterol (LDL-C) level (treat-to-target strategy), the other is to maintain high-intensity statin without a target goal (high-intensity statin strategy).

MedicalResearch.com Interview with: [caption id="attachment_60149" align="alignleft" width="150"]Philip Lazarus, PhDBoeing Distinguished Professor, Pharmaceutical Sciences
Professor, Dept of Pharmaceutical Sciences
College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, WA 99210 Dr. Lazarus[/caption] Philip Lazarus, PhD Boeing Distinguished Professor, Pharmaceutical Sciences Professor, Dept of Pharmaceutical Sciences College of Pharmacy and Pharmaceutical Sciences Washington State University Spokane, WA 99210   MedicalResearch.com: What is the background for this study? Response: Smoking and tobacco use remains a major health issue. Smokers use cigarette over the course of the day because the levels of nicotine, the addictive agent in cigarettes and other forms of tobacco, dimmish with time in the bloodstream due to the breakdown of nicotine by enzymes in the body. By inhibiting the breakdown of nicotine in smokers, one would expect that the levels of nicotine would remain higher after smoking a single cigarette, and that these individuals may not require lighting up another cigarette so quickly, reducing the number of cigarettes smoked over the course of a day. This could have a profound effect on reducing the overall harm incurred from smoking or from using other forms of tobacco. In a single previous study, smokers who used a CBD inhaler exhibited a 40% reduction in cigarette use. In addition, while cannabis users are often smokers, previous studies have indicated that they smoke less cigarettes than non-cannabis-using cigarette smokers. In previous studies published in 2021, we found that major cannabinoids present in cannabis like THC and CBD inhibit major metabolizing enzymes in our body, including several that are important in drug metabolism. We hypothesized that CBD and its major active metabolite, 7-hydroxy (OH)-CBD, may also be inhibiting one or more of the enzymes important in the metabolism (or breakdown) of nicotine.

MedicalResearch.com Interview with: [caption id="attachment_60144" align="alignleft" width="150"]Anna Roca PhDMRC Unit The Gambia at the London School of Hygiene and Tropical Medicine Fajara, The Gambia Dr. Roca[/caption] Anna Roca PhD MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine Fajara, The Gambia MedicalResearch.com: What is the background for this study? Response: Context specific interventions are needed to decrease the high burden of severe neonatal morbidity and mortality in sub-Saharan Africa. Severe bacterial infections are a main cause of neonatal mortality in the continent. Oral intra-partum azithromycin is a cheap intervention easily scalable. Before embarking on this trial, we conducted a proof-of-concept trial that showed the intervention reduced maternal and neonatal bacterial carriage of the most prevalent bacteria causing neonatal sepsis in the continent.

MedicalResearch.com Interview with: [caption id="attachment_60140" align="alignleft" width="112"]Dhruv Khullar, M.D., M.P.P.Director of Policy Dissemination Physicians Foundation Center for Physician Practice and Leadership Assistant Professor of Health Policy and Economics Weill Cornell Medicine, NYC Dr. Khullar[/caption] Dhruv Khullar, M.D., M.P.P. Director of Policy Dissemination Physicians Foundation Center for Physician Practice and Leadership Assistant Professor of Health Policy and Economics Weill Cornell Medicine, NYC   MedicalResearch.com: What is the background for this study? Response: From prior research, we know that there are racial/ethnic differences in the acute impact of COVID-19, including higher rates of hospitalization and death among Black and Hispanic individuals compared to white individuals. Less is known about whether there are differences in the rates or types of long COVID by race and ethnicity.

Editor's note: This piece discusses suicide. If you have experienced suicidal thoughts or have lost someone to suicide and want to seek help, you can contact the Crisis Text Line by texting "START" to 741-741 or call the Suicide Prevention Lifeline at 800-273-8255. MedicalResearch.com Interview with: [caption id="attachment_60131" align="alignleft" width="125"]Alexia AguilarGeisinger Commonwealth School of Medicine
Scranton, PA Alexia Aguilar[/caption] Alexia Aguilar Geisinger Commonwealth School of Medicine Scranton, PA     MedicalResearch.com: What is the background for this study? Response: Traditional antidepressants like Zoloft and Lexapro have three major drawbacks.
  • First, they have a therapeutic lag and take at least a couple weeks to begin to improve mood.
  • Second, they do not work very well for many patients with only about one-third experiencing a remission.1
  • Third, they carry a Food and Drug Administration black box warning for increasing the risk of suicide in young-adults. There is tremendous enthusiasm for the anesthetic ketamine and esketamine because they overcome all three of these limitations. The brand name of esketamine is Spravato. Spravato received conditional approval from the FDA in March of 2019 as a nasal spray for treatment resistant depression or acute suicidality.  The goal of this study was to examine prescriptions for ketamine and esketamine in 2019 and 2020.

MedicalResearch.com Interview with: [caption id="attachment_60128" align="alignleft" width="150"]Mario FL Gaudino, MD, PhD, MSCE, FEBCTS, FACC, FAHAStephen and Suzanne Weiss Professor in Cardiothoracic Surgery (II)
Assistant Dean for Clinical Trials
Professor of Clinical Epidemiology and Health Services Research at Weill Cornell Graduate School
Director of the Joint Clinical Trials Office (JCTO)
Director of Translational and Clinical Research, Department of Cardiothoracic Surgery
Chair Coronary Artery Task Force, European Association for Cardio-Thoracic Surgery

Weill Cornell Medicine | NewYork – Presbyterian Hospital
Department of Cardiothoracic Surgery Dr. Gaudino[/caption] Mario FL Gaudino, MD, PhD, MSCE, FEBCTS, FACC, FAHA Stephen and Suzanne Weiss Professor in Cardiothoracic Surgery (II) Assistant Dean for Clinical Trials Professor of Clinical Epidemiology and Health Services Research at Weill Cornell Graduate School Director of the Joint Clinical Trials Office (JCTO) Director of Translational and Clinical Research, Department of Cardiothoracic Surgery Chair Coronary Artery Task Force, European Association for Cardio-Thoracic Surgery Weill Cornell Medicine | NewYork – Presbyterian Hospital Department of Cardiothoracic Surgery MedicalResearch.com: What is the background for this study? Response: It is well-documented that women undergoing CABG have higher mortality and morbidity when compared with men. They are referred to surgery later than men, with more cardiovascular risk factors than men, and present more frequently with heart failure or in non-elective settings. However, overall CABG outcomes have improved over time, and so we sought to evaluate national trends in outcomes specifically in women.

Dementia is a condition that affects many older adults aged 65 years and older but is increasingly being diagnosed in much younger people. It is a tragic disease as the personality of the sufferer changes, they struggle to identify close family members, and there is a profoundly sad loss of dignity as the disease progresses. Medical researchers are very active in undertaking experiments to find better ways of early diagnosis and treating patients more effectively. We look at the more recent research in this regard.

Improved Digital Markers

Scientists have found a new method to predict dementia before its onset or while it is still mild. This allows those who are positively identified to make lifestyle changes to stay healthy for longer and to begin preparing for special care when they can no longer look after themselves. The research tests comprised a study of driving behaviors. This was a longitudinal study. It had a 96% accuracy and considered 200 driving elements. Just under 3000 test subjects participated in the study, which took place in five US states. All the participants were still driving their own vehicles as a way of retaining their independence as they entered the older age stages of life, with everyone being between 65 and 79 years of age. Eighty-five percent of this age group were found to still be driving at this stage of life. None had signs of cognitive decline. Follow-up of the participants took place three years after the testing phase. Sixty-one participants had gone on to develop Alzheimer’s disease, some cognitive decline, or other types of dementia. The researchers compared their results against two other popular methods (logistic regression and random forests) of predicting dementia and found that their test had a 6-10% greater accuracy than the rest. Two aspects of driving that were especially useful for predicting future dementia were how many times drivers braked hard with 0.4 g or greater deceleration and the ratio of right and left turns. Regarding the latter, older people found it less risky to turn right rather than left. Early warning of possible dementia later in life is essential to preparing for increasing levels of care, from overnight, to 24/7. Check out this guide if you want to know more about what is overnight care. Many dementia patients with mild impairment may start with this form of assistance. A bit of help when needed can allow the person to store their energy for greater independence in intimate activities like bathing.

If you have recently been diagnosed with Alzheimer’s disease, or indeed another memory-based illness, you will understandably be feeling as if you are falling into a hole of emotions. However, rather than being something that you are entirely not in control of, quite the opposite is true, and channeling how you...

MedicalResearch.com Interview with: [caption id="attachment_60080" align="alignleft" width="150"]Rishi K. Wadhera, MD, MPP, MPhilSection Head, Health Policy and Equity,
Richard A. and Susan F. Smith Center for Outcomes Research
Associate Program Director, Cardiovascular Medicine Fellowship at Beth Israel Deaconess Medical Center
Assistant Professor of Medicine,
Harvard Medical School Dr. Wadhera[/caption] Rishi K. Wadhera, MD, MPP, MPhil Section Head, Health Policy and Equity, Richard A. and Susan F. Smith Center for Outcomes Research Associate Program Director Cardiovascular Medicine Fellowship at Beth Israel Deaconess Medical Center Assistant Professor of Medicine, Harvard Medical School @rkwadhera MedicalResearch.com: What is the background for this study? Response: High and rising prescription drug costs in the United States contribute to medication non-adherence and financial strain among adults with cardiovascular risk factors or disease. As a result, addressing prescription drug costs in patients with chronic conditions has become a national priority. In response to these growing concerns, federal policymakers passed the Inflation Reduction Act on August 16, 2022, which aims to address high out-of-pocket drug costs for adults enrolled in Medicare Part D, by placing a $2000 annual cap on out-of-pocket prescription drug costs and expanding eligibility for full low-income subsidies to individuals that reduce deductible costs and prescription copayments (among several other provisions). It is unclear how these provisions will affect Medicare beneficiaries with cardiovascular risk factors and/or conditions.

MedicalResearch.com Interview with: [caption id="attachment_59720" align="alignleft" width="133"]James Stevermer, M.D., M.S.P.H. Vice chair for clinical affairs Professor of family and community medicine University of Missouri Medical director of MU Health Care Family Medicine–Callaway Physicians Dr. Stevermer[/caption] James Stevermer, M.D., M.S.P.H. Vice chair for clinical affairs Professor of family and community medicine University of Missouri Medical director of MU Health Care Family Medicine–Callaway Physicians, Dr. Stevermer joined the U.S. Preventive Service Task Force in January 2021.     MedicalResearch.com: What is the background for this study? Response: Genital herpes is a common sexually transmitted infection (STI) that unfortunately has no cure and cannot accurately be detected in people who do not have signs of the condition. The current screening tests have limitations and there is a high chance that test results will say a person has the condition when they do not. In addition, the available treatments are focused on managing symptoms and preventing the condition from reoccurring. As a result, the Task Force concluded that the harms of screening outweigh the benefits.

MedicalResearch.com Interview with: [caption id="attachment_60068" align="alignleft" width="150"]Jesse Goodrich PhDAssistant Professor Department of Population and Public Health Sciences Keck School of Medicine University of Southern California Dr. Goodrich[/caption] Jesse Goodrich PhD Assistant Professor Department of Population and Public Health Sciences Keck School of Medicine University of Southern California MedicalResearch.com: What is the background for this study? Response: Per- and poly-fluoroalkyl substances (PFAS) are a group of persistent chemicals that are known to interfere with hormones and metabolism. In our previous research, we have found that PFAS exposure is associated several specific diseases, especially in children and adolescents. These include obesity, type 2 diabetes, liver disease, and even liver cancer. However, we are still only just starting to fully understand all of the health effects of the many different PFAS in existence. Previous studies have focused primarily on one or two main PFAS. However, there are over 9,000 known PFAS, and people are exposed not just to a single PFAS but to mixtures of many PFAS. Importantly, the combination of these chemical exposures may affect us differently than single exposures alone. To address this challenge, we used an innovative approach to study design to examine how exposure to PFAS impacts biological processes which may underly the development of many different diseases in adolescents and young adults. To do this, we first measured thousands of naturally occurring chemicals, known as metabolites, in people's blood. Then, using a new biostatistical method developed by our team, we identified how exposure to a mixture of several PFAS impacted each individual chemical. Finally, we used this information to determine which biological processes are changed by PFAS exposure.

MedicalResearch.com Interview with: [caption id="attachment_60059" align="alignleft" width="125"]Yann Le Guen, Ph.D.Assistant Director, Computational Biology
Quantitative Sciences Unit
Stanford Medicine Dr. Yann Le Guen[/caption] Yann Le Guen, Ph.D. Assistant Director, Computational Biology Quantitative Sciences Unit Stanford Medicine MedicalResearch.com: What is the background for this study? Response: Apart from aging, the strongest contributing factor for late-onset Alzheimer’s disease is a specific allele of the APOE gene, which has three common alleles E2, E3, and E4. While E3 is the most common and considered as the reference, E2 is associated with decreased Alzheimer’s disease risk and E4 is associated with increased Alzheimer’s disease risk. Notably the prevalence of E4 among Alzheimer’s patient is high with about 60% of these carrying at least one E4 allele, while solely about 30% Americans carry one E4 allele. It’s worth emphasizing that individuals with an E4/E4 genotype have an exponential increased in their risk to develop AD (10 times as likely than the reference E3/E3 genotype), and individuals with an E3/E4 genotype have an intermediate risk. Though, most studies of Alzheimer’s disease genetic have been focused on European ancestry, this is beginning to change thanks to NIH’s efforts to fund more studies in non-European ancestry individuals. Our study built on these recent efforts to assess the Alzheimer disease risk associated with an APOE variant (R145C) present in about ~4% African Americans, but extremely rare in Europeans.

MedicalResearch.com Interview with: [caption id="attachment_60052" align="alignleft" width="125"]Michael Liu, MPhilRhodes Scholar,MPhil in Evidence-Based Social Intervention and Policy Evaluation.
Harvard Medical School
Boston, Massachusetts Michael Liu[/caption] Michael Liu, MPhil Rhodes Scholar,MPhil in Evidence-Based Social Intervention and Policy Evaluation. Harvard Medical School Boston, Massachusetts   MedicalResearch.com: What is the background for this study? Response: Over the past few decades, research has shown that lesbian, gay, and bisexual (LGB) individuals have worse health outcomes and face unique challenges related to their experiences and costs of care. These disparities are driven by “minority stress” associated with belonging to a marginalized group. Such stressors erode health through a range of structural and interpersonal forces, including employment discrimination, family rejection, and internalized stigma One early analysis established national baseline estimates for LGB health outcomes using 2013-2014 National Health Interview Survey (NHIS) data. Since then, there have been substantial shifts in social policy and public opinion that may have differentially affected sexual minority subgroups. The US Supreme Court decision in Obergefell v. Hodges guaranteed the constitutional right to same-sex marriage across all states. Over the last decade, states have expanded rights and protections for LGB populations related to employment and housing discrimination, sexual orientation conversion efforts, HIV criminalization, and religious exemptions. Public support for LGB-related issues has also been increasing with more representation in media, uptake of LGB-affirming policies, and advocacy efforts. No studies have assessed national trends in health status or healthcare access among specific sexual minority subgroups amid the rapidly shifting sociocultural and policy landscape. Thus, we sought out to evaluate if and how health status and healthcare access have changed between 2013 and 2018 in the US among LGB adults, and whether differences relative to their heterosexual counterparts have changed over time.

MedicalResearch.com Interview with: [caption id="attachment_60034" align="alignleft" width="130"]Shinobu Itagaki, MD, MScAssistant Professor Cardiovascular Surgery Icahn School of Medicine at Mount Sinai, New York, NY Dr. Itagaki[/caption] Shinobu Itagaki, MD, MSc Assistant Professor Cardiovascular Surgery Icahn School of Medicine at Mount Sinai, New York, NY MedicalResearch.com: What is the background for this study? Were the transplants from a single donor? Response: The heart transplantation is the gold standard therapy for end-stage heart failure patients. As the kidney is affected by the heart function, it is common that the heart transplant candidates have some degree of kidney dysfunction as well. In these cases, the candidates are considered for simultaneous heart and kidney transplantation from a same donor. Unlike isolated heart transplantation, where the indication and benefits have been well established, simultaneous heart and kidney transplantation has less clear indication and benefits. This uncertainty is also complicated by the competing interest with isolated kidney transplantation candidates who in general wait longer on the waiting list.

MedicalResearch.com Interview with: [caption id="attachment_60043" align="alignleft" width="100"]Natalie Shaw, M.D., MMSc.Principal Investigator Head of the Pediatric Neuroendocrinology Group Dr. Shaw holds a secondary appointment in NIEHS  Reproductive and Developmental Biology Laboratory. Dr. Shaw[/caption] Natalie Shaw, M.D., MMSc. Principal Investigator Head of the Pediatric Neuroendocrinology Group Dr. Shaw holds a secondary appointment in NIEHS Reproductive and Developmental Biology Laboratory.   MedicalResearch.com: What is the background for this study? Would you briefly describe the two affected conditions? Dr. Shaw: Congenital arhinia is a rare congenital malformation characterized by the complete absence of an external nose and internal olfactory (smell) structures.  It is frequently associated with eye and reproductive defects.  Facioscapulohumeral muscular dystrophy (FSHD) type 2 is a form of muscular dystrophy that presents in young adulthood.  Both conditions are caused by mutations in the gene SMCHD1.  In FSHD type 2, we know that loss of SMCHD1 activity leads to expression of a toxic protein called DUX4 in muscle.  The cause of arhinia was unknown.

If you have aging parents, the one thing you will want to be aware of is the most common health concerns that plague the elderly. While there is no way to definitively say who will suffer from any one of these diseases or conditions, they are most common among the elderly. For this reason, and because the elderly may be prone to memory lapses, it is important that you find a way to communicate with their primary health provider to ensure that everything is as it should be. With HIPAA in effect, you may need to get their approval to speak with their doctor or if they’ve been declared incompetent, the proper authorization from the courts would be necessary. At any rate, these are the health concerns you should be on the lookout for, as they truly are most prevalent in the elderly.

MedicalResearch.com Interview with: [caption id="attachment_58888" align="alignleft" width="200"]Ali Torkamani, Ph.D. Director of Genomics and Genome Informatics Scripps Research Translational Institute Professor, Integrative Structural and Computational Biology Scripps Research La Jolla, CA 92037 Dr. Torkamani[/caption] Ali Torkamani, Ph.D. Director of Genomics and Genome Informatics Scripps Research Translational Institute Professor, Integrative Structural and Computational Biology Scripps Research La Jolla, CA 92037 MedicalResearch.com:  What is the background for this study?  Response: Prior research has shown that people with higher polygenic risk for coronary artery disease achieve greater risk reduction with statin or other lipid lowering therapy. In general, adherence to standard guidelines for lipid lowering therapy is low - about 30% of people who should be on lipid lowering therapy are, with no correlation to their genetic risk. We set out to see whether communicating personalized risk, including polygenic risk, for coronary artery disease would drive the adoption of lipid lowering therapy.

MedicalResearch.com Interview with: [caption id="attachment_58894" align="alignleft" width="133"]Howard D. Sesso, ScD, MPH Associate Professor of Medicine Division of Preventive Medicine Brigham and Women's Hospital Dr. Sesso[/caption] Howard D. Sesso, ScD, MPH Associate Professor of Medicine Division of Preventive Medicine Brigham and Women's Hospital MedicalResearch.com:  What is the background for this study? How does the amount of flavanols in the study arm compare to what might be obtained in a typical diet? Response: The COcoa Supplement and Multivitamin Outcomes Study (COSMOS) is a randomized, double-blind, placebo-controlled clinical trial that tested the effects of two promising dietary supplements on cardiovascular disease (CVD) and cancer in 21,442 older adults. Cocoa flavanols have been shown to have favorable vascular effects in small and short-term clinical trials. The 500 mg/day flavanols tested in COSMOS exceeds that readily obtained in the diet typically from cocoa, tea, grapes, and berries. Of note, flavanol content in not typically listed on food labels. COSMOS also tested a multivitamin, the most common dietary supplement taken by US adults and previously linked with a potential modest reduction in cancer in a previous long-term trial of men conducted by our research group at the Division of Preventive Medicine at Brigham and Women’s Hospital.

MedicalResearch.com Interview with: Arman A. Shahriar Medical Student, University of Minnesota Medical School Research Consultant, HealthPartners Institute Minneapolis, MinnesotaArman A. Shahriar Medical Student, University of Minnesota Medical School Research Consultant, HealthPartners Institute Minneapolis, Minnesota

  MedicalResearch.com:  What is the background for this study?  Response: In recent years there has been a significant focus on the diversity of medical students, but to date, most work has focused on ‘visible’ forms of diversity; such as race, ethnicity and gender.

MedicalResearch.com Interview with: [caption id="attachment_58885" align="alignleft" width="200"]Rene Cortese, PhD Assistant Professor Department of Child Health – Child Health Research Institute Department of Obstetrics, Gynecology and Women’s Health School of Medicine Core Faculty - MU Institute for Data Science and Informatics University of Missouri Columbia, MO 65212 Dr. Cortese[/caption] Rene Cortese, PhD Assistant Professor Department of Child Health – Child Health Research Institute Department of Obstetrics, Gynecology and Women’s Health School of Medicine Core Faculty - MU Institute for Data Science and Informatics University of Missouri Columbia, MO 65212 MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: Obstructive sleep apnea (OSA) affects 22 million people in the U.S. and is linked to a higher risk of hypertension, heart attacks, stroke, diabetes, and many other chronic conditions. We have found that untreated OSA also accelerates the biological aging process, and that appropriate treatment can slow or possibly reverse the trend. Age acceleration testing involves a blood test that analyzes DNA and uses an algorithm to measure a person’s biological age. The phenomenon of a person’s biological age surpassing their chronological age is called “epigenetic age acceleration” and is linked to overall mortality and to chronic diseases.

MedicalResearch.com Interview with: Dr. Lora Shahine MD FACOG Host of the fertility podcast Baby or Bust https://www.lorashahine.com/ Dr. Shahine is double board-certified in reproductive endocrinology and infertility as well as obstetrics and gynecology Clinical assistant professor at the University of Washington Pacific NorthWest Fertility MedicalResearch.com: How did you become interested in reproductive medicine? Response: I love the combination of technology, women’s health, and helping people during a vulnerable time with all the emotions that come with it. I knew becoming a reproductive endocrinologist would mean a career of learning and helping people build families. MedicalResearch.com: When should women consider freezing their eggs?   Response: There is no one perfect age. The younger someone freezes eggs (in their 20s), the higher quality the eggs will be and the higher success in the future but the more likely someone may not need the. The older someone freezes eggs (in their late 30s and 40s), the lower quality and the lower chance of success over time. For many people and in general - the research supports its most cost effect to freeze eggs in your mid 30s.

MedicalResearch.com Interview with: [caption id="attachment_58881" align="alignleft" width="150"]Susan P. Y. Wong, MD MS Assistant Professor Division of Nephrology University of Washington VA Puget Sound Health Care System Dr. Wong[/caption] Susan P. Y. Wong, MD MS Assistant Professor Division of Nephrology University of Washington VA Puget Sound Health Care System  MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: Very little is known about the care and outcomes of patients who reach the end stages of kidney disease and do not pursue dialysis. We conducted a systematic review of longitudinal studies on patients with advanced kidney disease who forgo dialysis to determine their long-term outcomes. We found that many patients survived several years and experienced sustained quality of life until late in the illness course. However, use of acute care services was common and there was a high degree of variability in access to supportive care services near the end of life.

MedicalResearch.com Interview with: [caption id="attachment_58861" align="alignleft" width="128"]Lenore J. Launer Dr. Launer[/caption] Lenore J. Launer, Ph.D. Chief, Laboratory of Epidemiology and Population Sciences Intramural Research Program, National Institute on Aging. MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: Identifying early risk factors and early changes in the brain will have a major impact on future clinical and public health priorities related to the looming epidemic of dementia. Several studies based on older populations suggest mid-life is an important period to start prevention measures. To date control of blood pressure levels has been the most robust and promising candidate to target for prevention of future cognitive impairment. Although several studies have looked at levels of blood pressure and risk for cognitive impairment, it was not known whether trajectories from young adulthood to middle age studies provided additional information about risk. To investigate possible biomarkers of future risk, we chose to examine the association of the mean arterial blood pressure trajectories to indicators of pathology seen on MRI and that are associated with cognition. We highlight the results of the mean arterial blood pressure (MAP) measure, which is an integrated measure of systolic and diastolic blood pressure.